Related Experiment Video
Updated: Feb 3, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Multi-omics integration in deciphering non-small cell lung cancer drug resistance: current status, challenges, and
Jidong Miao1, Wenqiang Guan1, Jing Wang1
1Department of Oncology, Zigong Fourth People's Hospital, Zigong, Sichuan Province, 643000, China.
Abstract:
Lung cancer is the leading cause of cancer-related deaths globally. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, and drug resistance severely undermines treatment efficacy. This review summarizes recent advances in elucidating NSCLC drug-resistance mechanisms using multi-omics integration. Multi-omics integration systematically reveals the molecular networks of drug resistance, identifies key biomarkers and targets, and facilitates the screening of high-priority candidates for drug development through experimental validation. Small-molecule inhibitors targeting drug-resistant proteins and multi-omics-guided combination therapies offer strategies to reverse resistance. Future directions involve developing simultaneous multi-omics detection technologies, leveraging artificial intelligence for intelligent data analysis, establishing standardized frameworks for data sharing, and implementing personalized medicine based on multi-omics to improve patient prognosis.
Insights
This review highlights how multi-omics integration reveals non-small cell lung cancer (NSCLC) drug resistance mechanisms. It identifies biomarkers and therapeutic targets to overcome resistance and improve patient outcomes.
Area of Science:
- Oncology and Molecular Biology
- Genomics and Bioinformatics
Background:
- Lung cancer is the leading cause of cancer mortality worldwide.
- Non-small cell lung cancer (NSCLC) represents 85% of lung cancer cases.
- Drug resistance significantly limits the effectiveness of NSCLC treatments.
Purpose of the Study:
- To review recent advancements in understanding NSCLC drug resistance through multi-omics integration.
- To highlight the role of multi-omics in identifying resistance mechanisms, biomarkers, and therapeutic targets.
- To discuss strategies for overcoming drug resistance in NSCLC.
Main Methods:
- Systematic review of literature on multi-omics approaches in NSCLC research.
- Integration of diverse omics data (genomics, transcriptomics, proteomics, etc.) to analyze drug resistance.
- Identification of molecular networks and key players involved in treatment failure.
Main Results:
- Multi-omics integration provides a comprehensive view of NSCLC drug resistance pathways.
- Key biomarkers and drug targets for overcoming resistance have been identified.
- Small-molecule inhibitors and combination therapies show promise in reversing resistance.
Conclusions:
- Multi-omics integration is crucial for dissecting complex NSCLC drug resistance mechanisms.
- Targeted therapies and combination strategies guided by multi-omics data can enhance treatment efficacy.
- Future research should focus on advanced multi-omics technologies, AI-driven analysis, and personalized medicine for improved NSCLC patient prognosis.
Related Concept Videos
Treatment Resistant Cancers
Lung Capacity
Marcia's Theory of Identity Status
Resistivity
Resistance
Integration by Parts: Indefinite Integrals

